

Explanation of Changes to Preamble

2-Nitropropane:

See revised explanations on pp. 18 and 28. We have expanded on summarizing the methodology for not including 2-nitropropane in the Phase II risk analysis.

Economic Analyses:

See revised summary numbers on pp. 4, 50, and the table on p. 51. The table on p. 51 has split up the cost savings assumptions for the expanded de minimis exemption.

Section	Explanation
2-Nitropropane	See revised explanations on pp. 18 and 28. We have expanded on summarizing the methodology for not including 2-nitropropane in the Phase II risk analysis.
Economic Analyses	See revised summary numbers on pp. 4, 50, and the table on p. 51. The table on p. 51 has split up the cost savings assumptions for the expanded de minimis exemption.